Donanemab Slows Decline of Early Alzheimer’s

Donanemab Slows Decline of Early Alzheimer’s

Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of...
Grant Funds Alzheimer’s Smart Drug Delivery System

Grant Funds Alzheimer’s Smart Drug Delivery System

Rather than attempting to treat the multiple pathologies of Alzheimer’s disease individually, as is the current practice, researchers in the Buck Institute’s Andersen lab have designed a smart cell-based delivery system (SmaCD) to treat them all at once. The National...